151 related articles for article (PubMed ID: 15701883)
1. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
Johnston SR
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):889s-99s. PubMed ID: 15701883
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
Johnston SR
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
[TBL] [Abstract][Full Text] [Related]
3. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
4. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
5. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Johnston SR
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
[TBL] [Abstract][Full Text] [Related]
6. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
8. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
9. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.
Gligorov J; Azria D; Namer M; Khayat D; Spano JP
Crit Rev Oncol Hematol; 2007 Nov; 64(2):115-28. PubMed ID: 17702596
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
Johnston SR; Martin LA; Head J; Smith I; Dowsett M
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
[TBL] [Abstract][Full Text] [Related]
15. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
16. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
Pietras RJ
Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
[TBL] [Abstract][Full Text] [Related]
17. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
18. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
20. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]